Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer-How low can you go?

Breast

Volumn 16, Issue 4, 2007, Pages 420-424

  Yap, Y S ^a   Kendall, A ^a   Walsh, G ^a   Banerji, U ^a   Johnston, S R D ^a   Smith, I E ^a   O'Brien, M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Capecitabine; First line chemotherapy; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; TREATMENT DURATION;

EID: 34547202465     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.01.012     Document Type: Article

References (14)

1. Liu G., Franssen E., Fitch M.I., and Warner E. Patient preferences for oral vs. intravenous palliative chemotherapy. J Clin Oncol 15 1 (1997) 110-115
2. Borner M.M., Schoffski P., de Wit R., et al. Patient preference and pharmacokinetics of oral modulated UFT vs. intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38 3 (2002) 349-358
3. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 8 (1998) 1274-1281
4. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 2 (1999) 485-493
5. Blum J.L., Dieras V., Lo Russo P.M., et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92 7 (2001) 1759-1768
6. Leonard R.C., Twelves C., Breddy J., et al. Capecitabine named-patient programme for patients with advanced breast cancer, the UK experience. Eur J Cancer 38 15 (2002) 2020-2024
7. MacKean M., Planting A., Twelves C., et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16 9 (1998) 2977-2985
8. Hennessy B.T., Gauthier A.M., Michaud L.B., Hortobagyi G., and Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 16 8 (2005) 1289-1296
9. Bajetta E., Procopio G., Celio L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23 10 (2005) 2155-2161
10. El-Helw L., and Coleman R.E. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. The Breast 14 (2005) 368-374
11. O'shaughnessy J.A., Blum J., Moiseyenko V., et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12 9 (2001) 1247-1254
12. Fumoleau P., Largillier R., Clippe C., et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40 4 (2004) 536-542
13. Reichardt P., Von Minckwitz G., Thuss-Patience P.C., et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14 8 (2003) 1227-1233
14. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799